Company news
Inventisbio, Co., Ltd. Class A (SSE:688382) news
Inventisbio, Co., Ltd. Class A news releases on 6ix. Latest, Aug 26, 2026: "INVENTISBIO CO., LIMITED"Announcement on Convening the 2026 Semi-annual…
Press releases & updates
"INVENTISBIO CO., LIMITED"Announcement on Convening the 2026 Semi-annual Performance Briefing
August 25, 2026
"INVENTISBIO CO., LIMITED."Announcement on the Satisfaction of Vesting Conditions for the 3rd Vesting Period of the Reserved Grant under the 2022 Restricted Share Incentive Plan
August 21, 2026
"INVENTISBIO CO., LIMITED."Special Report on the Deposit, Management and Actual Use of Raised Funds for the First Half of 2026
August 20, 2026
"INVENTISBIO CO., LIMITED"Announcement on Signing Quadripartite Supervision Agreement for Deposit of Raised Funds in Special Account
July 22, 2026
"INVENTISBIO CO., LIMITED."Announcement on Abnormal Fluctuations in Stock Trading
July 3, 2026
"INVENTISBIO CO., LIMITED."Announcement on Adding Implementing Entities for Some Investment Projects Financed by Raised Funds and Opening Special Fundraising Accounts
July 2, 2026
Announcement on Granting Restricted Stocks to Incentive Objects of 2026 Restricted Stock Incentive Plan
June 24, 2026
Announcement on Resolutions of the 2025 Annual General Meeting
June 18, 2026
Publicity Explanation and Verification Opinions of Remuneration and Appraisal Committee of Board of Directors on List of Incentive Objects in 2026 Restricted Stock Incentive Plan
June 11, 2026
Announcement on Vesting Results of the 3rd Vesting Period of Those Initially Granted and the 2nd Vesting Period of Those Reserved for Grant (2nd Batch) in 2022 Restricted Stock Incentive Plan and Listing of Shares
June 1, 2026
Announcement on Resolutions of the 6th Meeting of the 2nd Board of Directors in 2026
May 28, 2026
Report for Q1 2026
April 28, 2026
Announcement on Achievements of Vesting Conditions in the 3rd Vesting Period of Those Initially Granted (2nd Batch) and the 2nd Vesting Period of Those Reserved for Grant in 2022 Restricted Stock Incentive Plan
April 14, 2026
Announcement on Convening the 2025 Annual Performance Briefing
April 9, 2026
Announcement on Termination of the 2025 Restricted Stock Incentive Plan
March 27, 2026
Announcement on Voluntary Disclosure of the Completion of Full Subject Enrollment in the Phase III Clinical Trial of D-2570 for Psoriasis
March 26, 2026
Announcement on Voluntary Disclosure of D-2570 Receiving Approval to Conduct Phase II Psoriasis Clinical Trial in the United States
March 18, 2026
Announcement on Resolutions of the 1st Extraordinary General Meeting in 2026
February 26, 2026
Announcement on Cancellation of Some Proposals at the 1st Extraordinary General Meeting in 2026
February 13, 2026
Notice on Convening the 1st Extraordinary General Meeting in 2026
February 10, 2026
Announcement on Expected Loss in Performance for 2025
January 29, 2026
Announcement on Listing and Circulation of Partial Restricted Shares in Initial Public Offering
January 16, 2026
Publicity Explanation and Verification Opinions of Remuneration and Appraisal Committee of Board of Directors on List of Incentive Objects in 2025 Restricted Stock Incentive Plan
January 7, 2026
Announcement on Resolutions of the 2nd Extraordinary General Meeting in 2025
December 25, 2025
Announcement on Abstract of 2025 Restricted Stock Incentive Plan (Draft)
December 19, 2025
Announcement on Resolutions of the 8th Meeting of the 2nd Board of Directors in 2025
December 9, 2025
Report for Q3 2025
October 29, 2025
Announcement on Convening the Q3 2025 Performance Briefing
October 28, 2025
Announcement on Progress in Litigation
September 29, 2025
Announcement on Vesting Results and Share Listing in the 2nd Vesting Period of Reserved Grant in 2022 Restricted Stock Incentive Plan
September 22, 2025
Announcement on Resolutions of the 1st Extraordinary General Meeting in 2025
September 8, 2025
Announcement on Changing Some Investment Projects Financed by Raised Funds
August 22, 2025
Announcement on Convening the 2025 Semi-annual Performance Briefing
August 18, 2025
Indicative Announcement on the Termination of the Acting-in-Concert Agreement Between the Controlling Shareholder, Actual Controller, and Their Party Acting in Concert, and the Resulting Change in Equity Interests
July 24, 2025
Announcement on Reply to Letter of Regulatory Inquiry on Information Disclosure of 2024 Annual Report
June 24, 2025
Announcement on Resolution of the 2024 Annual General Meeting
June 20, 2025
Announcement on Canceling Board of Supervisors, Changing Registered Capital and Amending the Articles of Association and Some Governance Systems
May 30, 2025
Announcement on Results of Shareholding Reduction by Shareholders
May 16, 2025
Indicative Announcement on Change in Shareholder's Equity
April 30, 2025
Report for Q1 2025
April 28, 2025
Special Report on Deposit and Actual Use of Raised Funds in 2024
April 25, 2025
Announcement on Convening the 2024 Annual Performance Briefing
April 18, 2025
Announcement on Shareholding Reduction Plan for Shareholders with Over 5% Shares
April 2, 2025
Announcement on Vesting Results of the 2nd Vesting Period of Those Initially Granted and the 1st Vesting Period of Those Reserved for Grant (2nd Batch) in 2022 Restricted Stock Incentive Plan and Listing of Shares
March 25, 2025
Indicative Announcement on Changes in Equity of Shareholders with Over 5% Shares and Persons Acting in Concert Reaching 1%
February 28, 2025
Announcement on Preliminary Earnings Estimate for 2024
February 25, 2025
Announcement on Resolutions of the 1st Meeting of the 2nd Board of Supervisors in 2025
January 17, 2025
Announcement on Share Reduction Plan for Shareholders
December 24, 2024
Announcement on Voluntary Announcement of Results of the Phase II Clinical Trial of D-2570
December 3, 2024
Announcement on Release of Pledge of Some Shares by Shareholders Holding More Than 5%
November 12, 2024